Reframing portal vein thrombosis in cirrhosis: A metabolic–endothelial disease beyond Virchow’s triad

Key Takeaways for GI Nurses

• Portal vein thrombosis (PVT) in cirrhosis is being reconceptualized as a metabolic–endothelial disorder rather than simply a consequence of the classic Virchow's triad (stasis, hypercoagulability, vessel injury) — a shift that may change how we assess risk in our patients.
• Patients with metabolic comorbidities (obesity, type 2 diabetes, metabolic-associated steatotic liver disease/MASLD) may warrant closer surveillance for PVT, since metabolic and endothelial dysfunction appear to be central drivers rather than incidental findings.
• Understanding this pathophysiologic shift helps nurses better anticipate complications during endoscopic procedures (variceal banding, TIPS pre/post-care) in cirrhotic patients who may have occult or evolving PVT.
• This research reinforces the importance of thorough pre-procedure chart review and communication with hepatology regarding anticoagulation status, especially as management paradigms for PVT continue to evolve.

Clinical Relevance

For nurses working in endoscopy and hepatology-focused GI units, portal vein thrombosis is a familiar but often underappreciated complication of cirrhosis that can complicate everything from variceal screening to transplant candidacy. This article's reframing of PVT as a metabolic–endothelial process — rather than a straightforward clotting problem — has practical implications for how we triage and monitor at-risk patients. As the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) rises, nurses should recognize that patients with cirrhosis secondary to metabolic syndrome may carry additional, less obvious risk for PVT beyond the traditional risk factors we're trained to screen for (prior thrombosis, malignancy, inherited coagulopathies).

From a practical standpoint, this evolving understanding may influence periprocedural care. Patients presenting for endoscopic variceal surveillance, banding, or TIPS evaluation should have vascular imaging and coagulation status reviewed with an eye toward endothelial and metabolic risk factors, not just standard hypercoagulability panels. Nurses performing pre-procedure assessments and medication reconciliation play a frontline role in flagging anticoagulant or antiplatelet use, glycemic control, and metabolic comorbidities that could be contributing to vascular risk. This is particularly relevant when coordinating care with hepatology and interventional radiology teams managing anticoagulation around endoscopic interventions, as bleeding risk from varices must be carefully balanced against thrombotic risk from PVT.

On a broader level, this research signals a potential shift in how multidisciplinary teams will approach PVT prevention and monitoring going forward — possibly incorporating metabolic risk stratification alongside traditional cirrhosis staging. GI nurses should stay engaged with evolving guidelines, as patient education around metabolic risk reduction (weight management, glycemic control, lipid management) could become a more integrated part of cirrhosis care pathways, not just an adjunct to liver disease management. Being conversant in this emerging framework also strengthens our ability to participate meaningfully in care conferences and advocate for comprehensive risk assessment in our cirrhotic patient population.

Bottom Line

This research suggests that portal vein thrombosis in cirrhosis is driven by more than mechanical clot-forming factors — metabolic and endothelial dysfunction appear to play a central role — meaning GI nurses should pay closer attention to metabolic comorbidities (obesity, diabetes, MASLD) as part of a comprehensive risk assessment for cirrh